EMA Application withdrawn: Exkivity (mobocertinib) — Takeda Pharma A/S

View source ↗

Summary

The EMA has withdrawn the application for Exkivity (mobocertinib) by Takeda Pharma A/S.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma Non-small-cell Lung Cancer

Drugs mentioned

• Exkivity (mobocertinib)

Snippet

Status: Application withdrawn. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Takeda Pharma A/S